E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Maintenance of remission in eosinophilic esophagitis |
Mantenimento della remissione della esofagite eosinofila |
|
E.1.1.1 | Medical condition in easily understood language |
Chronic allergic/immune-mediated inflammatory disease of the gullet in its remission phase |
Malattia allergica cronica / infiammatoria immunomediata dell'esofago nella sua fase di remissione |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10064220 |
E.1.2 | Term | Eosinophilic esophagitis |
E.1.2 | System Organ Class | 100000004856 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To prove superiority compared to placebo of episodic treatment with 4 cycles of budesonide 0.5 mg orodispersible tablets twice daily (BID) for 4 weeks followed by 8 weeks placebo BID over a total of 48 weeks and/or of continuous 48-week treatment with budesonide 0.5 mg orodispersible tablets BID in adult and adolescent eosinophilic esophagitis (EoE) patients in maintaining clinico-histological remission. |
comprovare la superiorità, confrontata con il placebo, di un trattamento episodico con 4 cicli di budesonide 0,5 mg compresse orodispersibili due volte al giorno (BID) per 4 settimane, seguiti da 8 settimane di placebo BID, per un totale di 48 settimane, e/o di un trattamento continuo di 48 settimane con budesonide 0,5 mg compresse orodispersibili BID in pazienti adulti e adolescenti affetti da esofagite eosinofila (EoE) per il mantenimento della remissione clinico-istologica |
|
E.2.2 | Secondary objectives of the trial |
Double-blind maintenance phase:
• To further assess EoE-associated clinical, endoscopic and histological findings after 48 weeks treatment for maintenance of remission,
• To study safety and tolerability as assessed by adverse events and laboratory parameters,
• To assess patients’ quality of life. |
Fase di mantenimento in doppio cieco: • valutare ulteriormente i risultati clinici, endoscopici e istologici associati all’EoE dopo 48 settimane di trattamento per il mantenimento della remissione; • studiare la sicurezza e la tollerabilità, valutate in base a eventi avversi e parametri di laboratorio; • valutare la qualità di vita dei pazienti. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Signed informed consent,
• Male or female patients, 16 to 75 years of age,
• Confirmed clinico-histological diagnosis of EoE according to established diagnostic criteria,
• Clinico-histological remission of EoE,
• Negative pregnancy test in females of childbearing potential at baseline visit
|
• consenso informato firmato • pazienti di sesso maschile o femminile, di età compresa tra 16 e 75 anni • diagnosi clinico-istologica confermata di EoE, in base a criteri diagnostici stabiliti • remissione clinico-istologica di EoE • test di gravidanza negativo per le pazienti di sesso femminile potenzialmente fertili alla visita basale |
|
E.4 | Principal exclusion criteria |
• Gastroesophageal reflux disease (GERD), • Achalasia, scleroderma esophagus, or systemic sclerosis, • Clinically evident causes for esophageal eosinophilia other than EoE, • Any concomitant esophageal disease and relevant active gastrointestinal disease, • Abnormal laboratory values, presence of or suspected relevant concomitant disease(s), that could affect study-specific assessments and/or their evaluation, or might compromise patient's safety and/or compliance (e.g. severe cardiovascular, renal, endocrine, psychiatric diseases/disorders, relevant infectious diseases associated with clinical signs, liver cirrhosis, portal hypertension, or uncontrolled cardiovascular disease, diabetes mellitus, osteoporosis, active peptic ulcer disease, glaucoma, cataract) • History of cancer, recent upper gastrointestinal bleeding, esophageal surgery, esophageal dilation procedures or need for an immediate endoscopic intervention due to a stricture • Diagnosis of chickenpox, herpes zoster, or measles within the last 3 months prior to baseline, • Treatment with medication, that could compromise/influence the effects of the study treatment, assessment of the endpoints and/or patients' safety, during or within too narrow timeframe of the clinical trial (e.g. systemic or oral glucocorticosteroids, immunosuppressants, CYP3A4 inhibitors, live vaccination, treatment with proton pump inhibitors, consumption of grapefruit) • Existing or intended pregnancy or breast-feeding. |
• malattia da reflusso gastroesofageo (MRGE) • acalasia, sclerodermia dell’esofago o sclerosi sistemica • cause con evidenza clinica di eosinofilia esofagea diverse dall’EoE • malattie esofagee concomitanti e malattia attiva gastrointestinale rilevante • valori di laboratorio anormali, presenza o sospette malattie concomitanti rilevanti, che potrebbero influenzare le valutazioni specifiche dello studio e / o la loro valutazione, o potrebbero compromettere la sicurezza e / o la compliance del paziente (ad es. Gravi malattie / disturbi cardiovascolari, renali, endocrini, psichiatrici , malattie infettive rilevanti associate a segni clinici, cirrosi epatica, ipertensione portale o malattia cardiovascolare non controllata, diabete mellito, osteoporosi, ulcera peptica attiva, glaucoma, cataratta) • anamnesi di cancro, recente emorragia del tratto gastrointestinale superiore, chirurgia esofagea, procedure di dilatazione esofagea o necessità di un intervento endoscopico immediato a causa di una stenosi • diagnosi di varicella, herpes zoster o morbillo nei 3 mesi precedenti alla visita basale • trattamento con farmaci che potrebbero compromettere / influenzare gli effetti del trattamento in studio, la valutazione degli endpoint e / o la sicurezza dei pazienti, durante o entro un arco di tempo troppo ristretto dello studio clinico (ad es. Glucocorticosteroidi sistemici o orali, immunosoppressori, inibitori del CYP3A4, vaccino vivo attenuato, trattamento con inibitori della pompa protonica, consumo di pompelmo) • gravidanza e allattamento, in corso o previsti |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of patients free of treatment failure after a 48 weeks DB treatment phase |
proporzione di pazienti senza fallimento del trattamento dopo una fase di trattamento in doppio cieco di 48 settimane |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
after 48 weeks of double-blind phase |
dopo 48 settimane dalla fase in doppio cieco |
|
E.5.2 | Secondary end point(s) |
• Proportion of patients with histological relapse at DB week 48
• Proportion of patients with clinical relapse, or who have experienced a food impaction, which needed endoscopic intervention during the DB treatment phase
• Proportion of patients in clinico-histological remission at DB week 48
|
• proporzione di pazienti con recidiva istologica alla settimana 48 in doppio cieco • proporzione di pazienti con recidiva clinica, o che hanno riferito un’ostruzione da bolo alimentare che ha richiesto intervento endoscopico durante la fase di trattamento in doppio cieco • proporzione di pazienti in remissione clinico-istologica alla settimana 48 in doppio cieco |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
after 48 weeks of double-blind phase |
dopo 48 settimane dalla fase in doppio cieco |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
In aperto: possibili fasi di 6 settimane per la induzione o la re-induzione della remissione |
Open-label: possible 6-week phases for induction or re-induction of remission |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 22 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Germany |
Italy |
Spain |
Switzerland |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 15 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 0 |